FDA Approves LEQSELVI — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries secured FDA approval for the oral deuruxolitinib phosphate formulation branded as LEQSELVI on July 25, 2024, reinforcing the company’s dermatology presence and signalling a new phase of commercialization expected to drive revenue growth. This milestone bolsters the firm's drug pipeline and positions the asset as a key contributor to its strategic market expansion.